Sign the letter
You don’t have to be affected to sign. We ask no health questions. Your signature counts once you confirm it from your email.
Already read the letter? Go straight to adding your name
A letter to the Church Pension Group and the Episcopal Church Medical Trust
We will deliver this letter, with every confirmed signature, before the Church Pension Fund’s trustees meet on December 9, 2026.
One Body
- Canon Anne M. Vickers, Chair, and the Board of Trustees of The Church Pension Fund
- Ms. Sandra Ferguson McPhee, Chair, Benefits Policy Committee
- Ms. Mary Kate Wold, President and CEO, Church Pension Group
- Mr. John Servais, Senior Vice President, Benefits Policy and Design
Dear Canon Vickers, Ms. Ferguson McPhee, Ms. Wold, Mr. Servais and members of the Board,
We write as members of the Episcopal Church Medical Trust and as people who care about them: clergy, lay employees, spouses and families, retirees, deputies, bishops, vestry members and clinicians.
We know the pressure you face. Without changes, 2027 rates would have risen 22.5 percent. Parishes, especially small ones, are struggling to pay what they owe. We thank you for the work of holding the plan together, and we share your goal: coverage the whole Church can afford.
We are writing about one decision: to exclude GLP-1 medications for weight loss from January 1, 2027, with no transition, no prior authorization and no medical-necessity review. We ask you to reconsider how this is being done.
People are being cut off mid-treatment with about ten weeks’ notice. Many members first learned of the change from individual letters in late October, after employers had chosen their 2027 plans. When these medicines are stopped, most of the benefit is lost within a year or two, including the weight lost and the improvements in blood pressure, blood sugar and cholesterol. The plan has already paid for much of that benefit.
The exclusion reaches uses that are not weight loss. The FDA has approved Wegovy to reduce heart attacks, strokes and cardiovascular deaths in people with heart disease, and to treat a serious liver disease, and Zepbound to treat sleep apnea.
Your own report points to a better path. The Medical Trust’s 2025 annual report credits its managed program with cutting the cost trend for these medicines from 148 to 62 percent and saving an estimated $3.2 million in one year. You have also said that the plan’s net cost is about twice what members can pay the manufacturers directly. That suggests ways to keep people in treatment for far less than full coverage.
We respectfully ask that you:
- Provide a transition of six to twelve months, at a higher copay if necessary, for members already in treatment.
- Keep coverage, through prior authorization, for FDA-approved uses that are not weight loss: cardiovascular risk reduction, obstructive sleep apnea and MASH.
- Publish clear, consistent answers about what remains covered and what help is available.
- For 2028, develop and price a middle path instead of a blanket exclusion. Options include a member cost-share tier, clinical criteria with a lifestyle program, one preferred medicine at a negotiated price, an optional rider for plan sponsors, or a tax-free plan contribution toward members’ direct purchases, applied at checkout, open to every eligible member and counted toward out-of-pocket limits.
- Share the analysis behind this decision, including whether your contract with Express Scripts limits the options above, and when it renews. Review the decision for 2028 with members, the CPG Client Council and plan sponsors. Resolution 2009-A177 promised a church-wide advisory committee representative of the broader Church, and you have told General Convention that the Client Council fills that role; this is the kind of decision it should review.
We offer this in the spirit of the body Saint Paul describes, in which “if one member suffers, all suffer together with it.” We would welcome the chance to work on it with you.
Faithfully yours,
Add your name at onebody.care/sign
Add your name
732 people have signed so far. See who has signed